New and experimental therapies for pulmonary hypertension

Clin Chest Med. 2001 Sep;22(3):539-45. doi: 10.1016/s0272-5231(05)70290-2.


Advances in the understanding of the molecular and cellular pathogeneses of PPH have led clinicians beyond simple pulmonary vasodilation as the only treatment for PPH and to a realization that what were previously believed to be irreversible vascular lesions may, in fact, be reversible. The development of agents that target the known endothelial and nonendothelial defects in patients with PPH is well underway. Clinicians are witnessing an exciting new era for physicians and patients dealing with this disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents / therapeutic use
  • Endothelin Receptor Antagonists
  • Endothelins / therapeutic use
  • Endothelium, Vascular / physiology
  • Epoprostenol / analogs & derivatives*
  • Epoprostenol / therapeutic use
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / physiopathology
  • Nitric Oxide / therapeutic use
  • Vasodilator Agents / therapeutic use


  • Antihypertensive Agents
  • Endothelin Receptor Antagonists
  • Endothelins
  • Vasodilator Agents
  • Nitric Oxide
  • beraprost
  • Epoprostenol
  • treprostinil